Friday, April 09, 2021 10:27:53 PM
Neurons Stripped of Their Identity Are Hallmark of Alzheimer's Disease, study finds
Researchers at the University of California San Diego have identified new mechanisms in neurons that cause Alzheimer’s disease. In particular, they discovered that changes in the structure of chromatin, the tightly coiled form of DNA, trigger neurons to lose their specialized function and revert to an earlier cell state. This results in the loss of synaptic connections, an effect associated with memory loss and dementia.
The findings are published Nov. 13 in Science Advances.
The study was founded on the question: how do neurons in patients with Alzheimer’s disease differ from neurons in healthy individuals?
“It’s a fundamental question that would provide the framework and foundation for understanding Alzheimer’s disease at the cellular level, and thus pave the path for novel therapeutic approaches,” said Shankar Subramaniam, professor of bioengineering at the UC San Diego Jacobs School of Engineering.
Subramaniam worked with an interdisciplinary team of engineers and neuroscientists at UC San Diego to answer this question. They started by taking human induced pluripotent stem cells derived from patients with familial Alzheimer’s disease, which is a hereditary form of Alzheimer’s, and transformed them into neurons. They used next generation sequencing techniques to look at what genes are being expressed in these neurons and how gene expression is regulated, and then compared how they differ in neurons of healthy individuals.
They discovered that neurons derived from the patients de-differentiate to a precursor state.
“In other words, they cease to be neurons,” Subramaniam said. “This is the key defect observed across a diversity of patients with distinct mutations. The consequences to the brain are dramatic, with loss of synaptic connections leading to cognitive decline.”
The researchers observed other defects: neuronal genes are suppressed, so these cells no longer have any instructions telling them that they are neurons; they are in a precursor-like state, which means they can trigger cell growth and division—this is unusual because adult brains do not produce new neurons; and they have inflammation, which signals damage or stress.
The same defects were also observed in post-mortem human brain samples from patients with Alzheimer’s disease. “This was validating for our findings because we weren’t just seeing these mechanisms in the stem cells, but in actual brain samples as well,” Subramaniam said.
The researchers traced all of these mechanisms back to changes in the structure of chromatin. Parts of this structure consist of open regions, where genes are expressed or regulated, and other parts consist of closed regions, where gene expression is repressed. In the diseased neurons, some regions that used to be open are now closed, and vice versa. As a consequence, the neurons are not behaving as they should be, Subramaniam explained.
The team is now working on developing drugs to inhibit these mechanisms.
Researchers at the University of California San Diego have identified new mechanisms in neurons that cause Alzheimer’s disease. In particular, they discovered that changes in the structure of chromatin, the tightly coiled form of DNA, trigger neurons to lose their specialized function and revert to an earlier cell state. This results in the loss of synaptic connections, an effect associated with memory loss and dementia.
The findings are published Nov. 13 in Science Advances.
The study was founded on the question: how do neurons in patients with Alzheimer’s disease differ from neurons in healthy individuals?
“It’s a fundamental question that would provide the framework and foundation for understanding Alzheimer’s disease at the cellular level, and thus pave the path for novel therapeutic approaches,” said Shankar Subramaniam, professor of bioengineering at the UC San Diego Jacobs School of Engineering.
Subramaniam worked with an interdisciplinary team of engineers and neuroscientists at UC San Diego to answer this question. They started by taking human induced pluripotent stem cells derived from patients with familial Alzheimer’s disease, which is a hereditary form of Alzheimer’s, and transformed them into neurons. They used next generation sequencing techniques to look at what genes are being expressed in these neurons and how gene expression is regulated, and then compared how they differ in neurons of healthy individuals.
They discovered that neurons derived from the patients de-differentiate to a precursor state.
“In other words, they cease to be neurons,” Subramaniam said. “This is the key defect observed across a diversity of patients with distinct mutations. The consequences to the brain are dramatic, with loss of synaptic connections leading to cognitive decline.”
The researchers observed other defects: neuronal genes are suppressed, so these cells no longer have any instructions telling them that they are neurons; they are in a precursor-like state, which means they can trigger cell growth and division—this is unusual because adult brains do not produce new neurons; and they have inflammation, which signals damage or stress.
The same defects were also observed in post-mortem human brain samples from patients with Alzheimer’s disease. “This was validating for our findings because we weren’t just seeing these mechanisms in the stem cells, but in actual brain samples as well,” Subramaniam said.
The researchers traced all of these mechanisms back to changes in the structure of chromatin. Parts of this structure consist of open regions, where genes are expressed or regulated, and other parts consist of closed regions, where gene expression is repressed. In the diseased neurons, some regions that used to be open are now closed, and vice versa. As a consequence, the neurons are not behaving as they should be, Subramaniam explained.
The team is now working on developing drugs to inhibit these mechanisms.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
